PALISADE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
PALISADE BIO, INC. (PALI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 76.05% for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2021-11-12
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2019-03-31 was 97.00%.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2012-03-31 was 70.61%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month |
|---|---|---|---|---|
| 2021-09-30 | 76.05% 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | 76.05% 10-Q · filed 2021-08-23 | |||
| 2020-09-30 | 80.00% 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | 80.00% 10-Q · filed 2021-08-23 | 110.00% 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | 97.00% 10-Q · filed 2020-05-15 | |||
| 2012-03-31 | 70.61% 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |